Clinical trial Recruiting at 1 site Observational

Analyzing cerebrospinal fluid in patients with delirium

Official title: MOLECULAR BIOMARKERS IN DELIRIUM AND DEMENTIA

Run by Oslo University Hospital · NCT05060614 · Data updated 2026-11-12

This study is trying to find out if certain markers in the spinal fluid of people with delirium, especially those who have had hip fractures, can help us understand how delirium is connected to dementia.

Quick facts

Study typeObservational
SexAll
Enrollment700 (estimated)
SponsorOslo University Hospital
Academic / other
Locations1 site (Oslo, Other)
StatusRecruiting
StartedSeptember 1, 2016
Main results expectedDecember 30, 2027
Study endsDecember 30, 2027
Registry record updatedMarch 12, 2024
Trial IDNCT05060614 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are patients with acute hip fractures who are experiencing delirium.

Probably not a fit

Patients who are moribund or unable to provide consent will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to measure biomarkers in cerebrospinal fluid (CSF) and serum samples from patients experiencing delirium, particularly those with acute hip fractures. By investigating these biomarkers, the study seeks to uncover insights into the pathophysiology of delirium and its potential connections to dementia. The research focuses on understanding the molecular mechanisms that may link these two conditions, which share clinical and epidemiological features. The findings could enhance our knowledge of delirium and its implications for dementia progression.

Why it matters

Potential benefit: If successful, this study could lead to improved understanding and management of delirium, potentially reducing its impact on dementia progression.

How similar studies have gone: While the exploration of biomarkers in delirium is an emerging field, similar studies have shown promise in understanding the connections between acute cognitive disturbances and neurodegenerative conditions.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with acute hip fracture

Exclusion Criteria:

* Moribund patients.
* Lack of consent

Where it's running

  • Leiv Otto Watne
    Oslo, Other, Norway
    Recruiting

Study contacts

  • Principal investigator: Leiv O Watne, PhD — Oslo University Hospital
  • Study coordinator: Leiv O Watne, PhD
  • Email: l.o.watne@gmail.com
  • Phone: 40203712

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.